Piramal

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Pharmaceutical, Health, Knowledge, NYSE, CDMO, Teva Active Pharmaceutical Ingredients, TEVA, Pivot, Growth, Agro, API, P&L, TASE, Patient, Piramal, Generic drug, Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).
  • Richard Francis, Teva’s President and CEO said: “I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business.
  • Having led the former Teva api and Biologics Operations organization at Teva from 2014 to 2018, Dr. Ananth has a deep understanding of Teva’s API business.
  • Dr. Ananth stated, “I am very excited to return to Teva to lead the API business, and to join my esteemed colleagues and teams at Teva api – old and new.

PIRAMAL PHARMA SOLUTIONS SUPPORTS THERACOSBIO WITH INTEGRATED DRUG SUBSTANCE/DRUG PRODUCT PROGRAM FOR BEXAGLIFLOZIN

Retrieved on: 
Thursday, March 30, 2023
BSE, Partnership, Piramal, PPL, API, Element, SGLT2, NSE, CDMO, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Fine chemical, Pharmaceutical industry, Morpeth, Bexagliflozin

The U.S. Food and Drug Administration (FDA) approved Brenzavvy, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, in January 2023.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved Brenzavvy, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, in January 2023.
  • Piramal Pharma Solutions and TheracosBio began their bexagliflozin partnership at Piramal's Ahmedabad, India site, where the manufacturing process for the tablet form was first established.
  • According to Peter DeYoung, Chief Executive Officer, Piramal Global Pharma, "Our partnership with TheracosBio is an important example of how an integrated services offering can benefit a client.
  • We are very proud of the work we have done and we congratulate TheracosBio on reaching this important milestone."

PIRAMAL PHARMA SOLUTIONS SUPPORTS THERACOSBIO WITH INTEGRATED DRUG SUBSTANCE/DRUG PRODUCT PROGRAM FOR BEXAGLIFLOZIN

Retrieved on: 
Thursday, March 30, 2023
BSE, Partnership, Piramal, PPL, API, Element, SGLT2, NSE, CDMO, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Fine chemical, Pharmaceutical industry, Morpeth, Bexagliflozin

The U.S. Food and Drug Administration (FDA) approved Brenzavvy, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, in January 2023.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) approved Brenzavvy, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, in January 2023.
  • Piramal Pharma Solutions and TheracosBio began their bexagliflozin partnership at Piramal's Ahmedabad, India site, where the manufacturing process for the tablet form was first established.
  • According to Peter DeYoung, Chief Executive Officer, Piramal Global Pharma, "Our partnership with TheracosBio is an important example of how an integrated services offering can benefit a client.
  • We are very proud of the work we have done and we congratulate TheracosBio on reaching this important milestone."

PIRAMAL PHARMA SOLUTIONS ANNOUNCES PRODUCTION OF FIRST BATCHES AT NEW API FACILITY IN RIVERVIEW, MICHIGAN

Retrieved on: 
Wednesday, February 15, 2023
Aurora, Oleśnica, NSE, Project, API, Pressure, PPL, CAD, Filtration, CDMO, Fine chemical, Piramal

Construction of the capacity expansion at Riverview, known as Project PRIME (Piramal Riverview Integrated Manufacturing Expansion) Phase 1, was kicked off in May of 2021.

Key Points: 
  • Construction of the capacity expansion at Riverview, known as Project PRIME (Piramal Riverview Integrated Manufacturing Expansion) Phase 1, was kicked off in May of 2021.
  • The initial production run is the culmination of a capital expenditure of $38 million in equipment and construction costs.
  • The facility covers approximately 25,000 square feet of space and includes production, warehousing and supporting utilities.
  • According to Peter DeYoung, Chief Executive Officer, Piramal Global Pharma, "Getting Project PRIME Phase 1 online is an important milestone for Piramal Pharma Solutions and the Riverview site team.

PIRAMAL PHARMA SOLUTIONS ANNOUNCES PRODUCTION OF FIRST BATCHES AT NEW API FACILITY IN RIVERVIEW, MICHIGAN

Retrieved on: 
Wednesday, February 15, 2023
Aurora, Oleśnica, NSE, Project, API, Pressure, PPL, CAD, Filtration, CDMO, Fine chemical, Piramal

Construction of the capacity expansion at Riverview, known as Project PRIME (Piramal Riverview Integrated Manufacturing Expansion) Phase 1, was kicked off in May of 2021.

Key Points: 
  • Construction of the capacity expansion at Riverview, known as Project PRIME (Piramal Riverview Integrated Manufacturing Expansion) Phase 1, was kicked off in May of 2021.
  • The initial production run is the culmination of a capital expenditure of $38 million in equipment and construction costs.
  • The facility covers approximately 25,000 square feet of space and includes production, warehousing and supporting utilities.
  • According to Peter DeYoung, Chief Executive Officer, Piramal Global Pharma, "Getting Project PRIME Phase 1 online is an important milestone for Piramal Pharma Solutions and the Riverview site team.

Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions

Retrieved on: 
Wednesday, January 4, 2023
Skin, Molluscum contagiosum, NDA, Disease, Technology transfer, Patient, Piramal, FDA, Therapy, Dermatology, Fine chemical

WEST CHESTER, Pa., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the successful completion of the technology transfer of bulk solution manufacturing to Piramal Pharma Solutions. The technology transfer includes the completion of the registration batch material, which has been placed on stability, and the manufacture of three process validation batches of bulk solution.

Key Points: 
  • WEST CHESTER, Pa., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the successful completion of the technology transfer of bulk solution manufacturing to Piramal Pharma Solutions.
  • The technology transfer includes the completion of the registration batch material, which has been placed on stability, and the manufacture of three process validation batches of bulk solution.
  • “We are pleased to have completed the technology transfer of bulk solution manufacturing for VP-102 to Piramal Pharma Solutions,” said Ted White, Verrica’s President and Chief Executive Officer.
  • We would like to thank Piramal Pharma Solutions, and their entire staff at the Sellersville, PA location, who have been true partners in this tech transfer process.

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Exercise, Skin, Company, CMC, CRL, Genetically modified bacteria, Dermatology, Collaboration, Squamous cell carcinoma, Fomite, U.S. Securities and Exchange Commission, Pharmacokinetics, Inflammation, Research, GAAP, Patient, Private Securities Litigation Reform Act, Wart, Itch, Mission statement, Achievement, United, Clinical trial, Social stigma, Physician, Sibling, Table, Molluscum contagiosum, NDA, FDA, Caregiver, Income, GLOBE, Cantharidin, Technology transfer, Safety, Disease, Pain, Therapy, Pharmaceutical industry, Reinsurance, Air cargo, Torii, Piramal, Chemistry

WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.

Key Points: 
  • WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022.
  • Research and development expenses were $2.9million in the third quarter of 2022, compared to $3.8 million for the same period in 2021.
  • General and administrative expenses were $3.9million in the third quarter of 2022, compared to $8.0 million for the same period in 2021.
  • As of September 30, 2022, Verrica had aggregate cash, cash equivalents, marketable securities and restricted cash of $39.5million.

Global OTC Topical Drugs Market Report 2022: Increasing Number of Skin Diseases and the Prevalence of Musculoskeletal Pain Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Health, Pharmaceutical, Cream, Online, Skin, Prevalence, Growth, Country, Population, Drug class, Analgesic, Distribution, Pfizer, Antibiotic, Piramal, Novartis, Global, APAC, Research, Astringent, Crowding, Pain management, Investment, Skin condition, Sanofi, MEA, Mometasone, Industry, Personal care, Teva Pharmaceuticals, Market share, Lists of diseases, OTC, Lists of countries and territories, Hospital, Life expectancy, Formulation, COVID-19, USD, Consumer, Eye, Pharmaceutical industry, Medical device, Health insurance, Healthcare, Petroleum jelly, Antipruritic, Bayer, Lotion

According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.

Key Points: 
  • According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.
  • The global OTC Topical Drugs Market is driven by an increasing number of skin diseases and the prevalence of musculoskeletal pain across the globe.
  • The report analyses the OTC Topical Drugs Market By Indication (Skin Disease management, Pain Management, Eye and Ear care, Others)
    The report analyses the OTC Topical Drugs Market by End User (Personal Care, Hospitals and clinics and others).
  • The Global OTC Topical Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

Yapan Bio Adds New Process Development Facility; Expands Capacity and Capabilities in Large Molecule Therapeutics

Retrieved on: 
Tuesday, October 18, 2022
API, Allergan, Commerce, Founder, Growth, Ministry of Industry, Commerce and Supplies (Nepal), The Carlyle Group, Ophthalmology, Vaccine, GMP, CGMP, Patient, Contract, Human, RNA, PPL, Plasmid, Partnership, McNeil Consumer Healthcare, PPS, Industry, E&C, CDMO, IAS, Information technology, Principal, Clinical trial, DNA, PCC, Solution, Strategic business unit, Fine chemical, Piramal, Genome Valley, Alvin Yapan

The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure.

Key Points: 
  • The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure.
  • Rama Rao stated,"It is heartening to see that Yapan Bio and Piramal Pharma have been continuously expanding from Genome Valley.
  • It's evidence of our commitment to Yapan and the large molecule CDMO business, as well as our commitment to patients.
  • In 2021, Piramal Pharma Solutions made an equity investment in Yapan Bio, enabling Yapan to take the business through its next phase of growth.

Piramal Pharma unveils its Sustainability Report FY21-22, articulating its ESG journey to accelerate the pace of integrating sustainability practices

Retrieved on: 
Thursday, October 13, 2022
Well, Zero, Allergan, Water, CSR, Quality, Growth, Coal, Ophthalmology, The Carlyle Group, ICH, ESG, Piramal, Tree, Patient, Sustainability, Report, Comparison of file archivers, Piramal Group, Workforce, PPL, Partnership, Goal, PSCI, Company, PPS, CDMO, CEO, CHG, Workplace, United Kingdom, Climate change, Chairperson, PCC, EHS, Renewable energy, Fine chemical, Audit, Environment

To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22

Key Points: 
  • To view the Company's ESG strategy, framework and targets, please download the full report: PPL Sustainability Report FY21-22
    Nandini Piramal, Executive Director of Piramal Enterprises and Chairperson of Piramal Pharma Limited, says, "Piramal has always prioritised sustainability practices at its core across all its operations.
  • Our second Sustainability Report is a manifestation of the progress of this journey and provides our stakeholders with a transparent view of our ESG performance.
  • This year, PPLundertook specific objective targets and timelines to achieve its ESG goals as the next steps in its ESG journey.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.